17,261 trials
Vitrectomy
Primary: Percentage of Eyes With Total Macular Posterior Vitreous Detachment (PVD). — 50; 62.5 percentage of eyes — p=0.679
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants
Rheumatoid Arthritis
Primary: Mean Injection Site Pain on a Visual Analogue Scale (VAS) — 3.3; 1.6 cm
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
Primary: Number of Participants Who Achieved a Complete Response — 47 Participants
Acute Myeloid Leukemia · Acute Myeloid Leukemia With Myelodysplasia-Related Changes · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Primary: Number of Participants Who Completed Maintenance Decitabine. — 62 participants
Rheumatoid Arthritis
Primary: Mean Injection Site Pain on a Visual Analogue Scale (VAS) — 4.2; 0.9 cm
Childhood High-grade Cerebellar Astrocytoma · Childhood High-grade Cerebral Astrocytoma · Recurrent Childhood Anaplastic Astrocytoma
Primary: Objective Response to Cilengitide — 1; 23 participants
Hepatitis C
Primary: Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period — 87.5; 83.3; 86.7; 85.7 percentage of participants
Oral Chronic Graft-versus-host Disease
Primary: The Clinical Efficacy of Topical Steroid and Topical Tacrolimus Therapies for the Treatment of Oral cGHVD. — 15; 3; 11; 2 participants
Hepatitis C Virus
Primary: Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period — 97.9; 97.9; 100.0; 96.0 percentage of participants
Idiopathic Pulmonary Fibrosis
Primary: Forced Vital Capacity (FVC) at Baseline and End of Period 1 — 2.74; 2.83; 2.40; 2.57 litres — p=0.9631
Human Influenza
Primary: Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV — 46; 89; 43; 90…
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any On-treatment Adverse Event (AE) or Any On-treatment Serious Adverse Event (SAE) — 6; 2; 8; 5 participants
Malignant Neoplasms of Brain
Primary: Humoral and Cellular Immune Response — 3; 0; 7 participants
Prostate Cancer
Primary: Number of Participants Showing a 50% Reduction in Serum Prostate Specific Antigen(PSA) During Treatment — 0 participants